Core Points - The company announced the results of the second vesting period for its 2023 restricted stock incentive plan, with 527,660 shares to be listed on August 6, 2025, representing 0.25% of the company's total share capital before vesting [2][3][4] Group 1: Stock Incentive Plan Details - The stock listing type is for equity incentive shares, with a total of 527,660 shares to be listed [2][3] - The decision-making process for the stock vesting was approved by the board and supervisory committee on June 26, 2023, and the plan was publicly disclosed on June 27, 2023 [4][5][6] - The number of individuals eligible for the stock vesting is 97, with the actual number of shares vesting being 527,660 [12][13] Group 2: Stock Listing and Capital Changes - The listing date for the vested shares is set for August 6, 2025, and the total share capital will increase from 211,571,033 shares to 212,098,693 shares [14][17] - The company received a total of RMB 11,904,009.60 from the 97 participants in the stock incentive plan, which includes an increase in share capital of RMB 527,660 [17] - The impact of the new shares on the company's financial report is minimal, with the diluted earnings per share remaining stable [18] Group 3: Convertible Bond Adjustments - The company announced an adjustment to the conversion price of its convertible bonds ("Hao Yuan Convertible Bonds") due to the completion of the stock vesting [19][20] - The conversion price was adjusted from RMB 40.59 to RMB 40.55 per share, effective from August 5, 2025 [23][26] - The adjustment was made in accordance with the company's regulations and relevant laws, ensuring the protection of bondholders' rights [24][25]

Group 1 - The China Convertible Bond Index closed down 0.08% at 460.63 points on July 30 [1] - Qizheng Convertible Bond increased by 12.40%, Sheyan Convertible Bond rose by 8.14%, and Punaite Convertible Bond gained 6.03% [1] - Tongguang Convertible Bond fell by 8.82%, Haoyuan Convertible Bond decreased by 7.28%, and Bojun Convertible Bond dropped by 6.04% [1]

Group 1 - The board of Tian23 Convertible Bond proposed a down adjustment [1] - A shareholder of Aotewei plans to reduce their stake by no more than 1.37% [1] - Meijin Energy's largest shareholder, Meijin Energy Group, has pledged all of its shares, totaling 35.32 million shares, which accounts for 2.15% of its holdings and 0.80% of the company's total share capital [1] - As of July 28, 2025, Meijin Group's cumulative pledged shares represent 100% of its total holdings [1] - Haoyuan Convertible Bond and Huicheng Convertible Bond will not be forcibly redeemed [1] - Yinwei Convertible Bond and Guowei Convertible Bond will not undergo down adjustment [1]

Group 1 - The company issued 8,223,500 convertible bonds with a total value of 82,235,000 RMB, each with a face value of 100 RMB, and a maturity of 6 years [1][2] - The controlling shareholder, Shanghai Anxu Information Technology Co., Ltd., acquired 2,653,870 bonds, representing 32.27% of the total issuance [2] - From July 8 to July 14, 2025, the controlling shareholder reduced its holdings by 925,460 bonds, bringing the total holdings down to 1,728,410 bonds, which is 21.02% of the total issuance [2]

Group 1 - The stock price of Haoyuan Pharmaceutical (688131) closed at 51.89 yuan on July 4, 2025, with an increase of 3.26% and a trading volume of 81,700 shares, resulting in a transaction amount of 420 million yuan [1] - On July 4, the net inflow of main funds was 20.6555 million yuan, accounting for 4.92% of the total transaction amount, while retail investors had a net outflow of 38.5298 million yuan, accounting for 9.18% [1][4] - The company announced a share repurchase and cancellation of 47,725 shares due to the failure of a performance commitment by a related party, resulting in a change in total share capital from 211,609,573 shares to 211,561,848 shares [1][4] Group 2 - The convertible bond "Haoyuan Convertible Bond" will have its conversion price adjusted from 40.58 yuan to 40.59 yuan per share, effective from July 8, 2025, following the share repurchase [2] - The bond will be suspended from conversion starting July 7, 2025, and will resume on July 8, 2025 [2][4] - The company issued 822.35 million yuan of convertible bonds with a maturity of six years, with an initial conversion price of 40.73 yuan per share [2]

Core Points - The company announced an adjustment to the conversion price of its convertible bonds "Hao Yuan Convertible Bonds" due to the completion of share repurchase and cancellation related to performance commitments [1][3] - The previous conversion price was 40.58 CNY/share, and the new conversion price is adjusted to 40.59 CNY/share, effective from July 8, 2025 [2][5] - The company issued 822,350 lots (8,223,500 bonds) of convertible bonds totaling 82,235 million CNY, with a maturity of 6 years and an initial conversion price of 40.73 CNY/share [2][3] Adjustment Basis - The adjustment of the conversion price is based on the completion of the repurchase and cancellation of 47,725 shares at a total price of 1.00 CNY, as approved in board meetings and the annual shareholders' meeting [3][4] - The company followed the regulations set by the China Securities Regulatory Commission regarding the issuance of convertible bonds and the related adjustments to protect the rights of bondholders [3][5] Adjustment Methodology - The adjustment formula used for the conversion price is P1 = (P0 + A × k) / (1 + k), where P0 is the previous conversion price, A is the new share price, and k is the rate of share repurchase [5] - The calculation resulted in the new conversion price of approximately 40.59 CNY/share after the repurchase and cancellation of shares [5][6]

Core Viewpoint - The company announced that the conversion price of its convertible bonds, "Haoyuan Convertible Bonds," will remain unchanged at RMB 40.58 per share following the completion of its stock incentive plan [1][4][6] Group 1: Convertible Bond Issuance - The company has received approval from the China Securities Regulatory Commission to issue convertible bonds totaling RMB 822.35 million, with a maturity of 6 years and an initial conversion price set at RMB 40.73 per share [1] - The bonds will be listed on the Shanghai Stock Exchange on December 19, 2024, with a total issuance of 822,350 lots (8,223,500 bonds) [1] Group 2: Stock Incentive Plan and Price Adjustment - The company completed the registration of the third vesting period of its 2022 restricted stock incentive plan on June 30, 2025, increasing its total share capital from 210,961,003 shares to 211,609,573 shares [2] - The adjustment of the conversion price is based on the company's stock incentive plan and follows specific formulas outlined in the bond issuance prospectus [3][5] Group 3: Price Adjustment Calculation - The conversion price remains unchanged at RMB 40.58 per share because the total number of shares from the stock incentive plan is relatively small compared to the total share capital [4][6] - The calculation for the conversion price adjustment was performed using the formula for new share issuance, resulting in no change to the conversion price [5][6]

Core Points - Shanghai Haoyuan Pharmaceutical Co., Ltd. issued 8.2235 million convertible bonds with a total amount of 82.235 million RMB, with a maturity of 6 years [1] - The convertible bonds, named "Haoyuan Convertible Bonds," will be listed on the Shanghai Stock Exchange starting December 19, 2024 [1] - The initial conversion price is set at 40.73 RMB per share, effective from June 4, 2025, until November 27, 2030 [2] Convertible Bond Issuance Overview - The company completed the registration procedures for the first vesting period of the 2022 restricted stock incentive plan, increasing the total share capital from 210,928,884 shares to 210,959,781 shares [2] - The conversion price of the "Haoyuan Convertible Bonds" remains unchanged at 40.73 RMB per share after the completion of the vesting [2] - The conversion price will be adjusted to 40.58 RMB per share starting May 14, 2025, due to the annual equity distribution [3] Conversion Status - From June 4, 2025, to June 30, 2025, a total of 1,222 shares were converted from the "Haoyuan Convertible Bonds," representing 0.0006% of the total shares before conversion [4] - As of June 30, 2025, the amount of unconverted bonds stands at 822.3 million RMB, accounting for 99.99% of the total issuance [5] Share Capital Changes - Following the completion of the vesting procedures, the total share capital increased to 211,609,573 shares, with 648,570 shares from the incentive plan becoming tradable on July 8, 2025 [5] Additional Information - Investors can refer to the detailed prospectus for the "Haoyuan Convertible Bonds" issued on November 26, 2024, for more information [6]

Summary of Key Points Core Viewpoint Shanghai Haoyuan Pharmaceutical Co., Ltd. has announced the issuance of convertible bonds, "Haoyuan Convertible Bonds," with a total amount of 82,235,000 RMB, which will be listed on the Shanghai Stock Exchange starting December 19, 2024. The bonds have a six-year term and specific terms for conversion into shares. Group 1: Issuance Details - The company will issue 8,223,500 convertible bonds, each with a face value of 100 RMB, totaling 82,235,000 RMB [1][3] - The bonds will be listed for trading on the Shanghai Stock Exchange under the code "118051" and the name "Haoyuan Convertible Bonds" starting December 19, 2024 [1] - The bond's term is six years, from November 28, 2024, to November 27, 2030 [1] Group 2: Conversion Terms - The coupon rates for the bonds are set to increase over the years, starting at 0.20% in the first year and reaching 2.00% in the sixth year [1] - The conversion period for the bonds will be from June 4, 2025, to November 27, 2030, with a current conversion price of 40.58 RMB per share [2][4] Group 3: Conversion Process - Holders can apply for conversion during the specified period on trading days, with the conversion process managed by the China Securities Depository and Clearing Corporation [2] - Newly converted shares will be listed for trading the day after the conversion application is approved [4] Group 4: Price Adjustment Mechanism - The initial conversion price was set at 40.73 RMB per share but has been adjusted to 40.58 RMB due to the company's stock incentive plan [5][6] - The conversion price may be adjusted based on various corporate actions, including stock dividends and capital increases [6][7] Group 5: Redemption and Sale Rights - The company has the right to redeem the bonds at 113% of the face value within five trading days after maturity if they remain unconverted [10] - Holders can sell back their bonds to the company if the stock price falls below 70% of the conversion price during the last two interest years [10][11] Group 6: Additional Information - Investors seeking more details can refer to the company's prospectus published on November 26, 2024, on the Shanghai Stock Exchange website [12]

证券代码：688131 证券简称：皓元医药 公告编号：2025-049 转债代码：118051 转债简称：皓元转债 上海皓元医药股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 本次会议是否有被否决议案：无 一、会议召开和出席情况 （一）股东大会召开的时间：2025年4月18日 （二）股东大会召开的地点：上海市浦东新区张衡路1999弄3号楼公司会议室 （三）出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及其持有表决权数量的情 况： ■ 注：本次股东大会公司股份总数为210,959,781股，有表决权股份数量（剔除公司2024年员工持股计划账 户股份数量5,693,012股）为205,266,769股。 （五）公司董事、监事和董事会秘书的出席情况 1、公司在任董事7人，出席7人，其中董事郑保富先生、Xiaodan Gu（顾晓丹）先生、独立董事李园园 女士以通讯方式出席了本次会议； （四）表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 本 ...